Visualitza per autor "Yaeger, Rona"
Ara mostrant els elements 1-5 d 5
-
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Tabernero Caturla, Josep; Grothey, Axel; Van Cutsem, Eric; Wasan, Harpreet; Yoshino, Takayuki; Yaeger, Rona (American Society of Clinical Oncology, 2021-02-01) -
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
Tabernero Caturla, Josep; Velez, L; Trevino, T. L.; Grothey, Axel; Van Cutsem, Eric; Yaeger, Rona (Elsevier, 2021-12) -
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Randon, Giovanni ; Nakamura, Yoshiaki; CREMOLINI, CHIARA; Yaeger, Rona; Lonardi, Sara; Elez, Elena; Ros, Javier (American Association for Cancer Research, 2024-01-15) -
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer
Yaeger, Rona; Siu, Lillian; Ducreux, Michel; Van Cutsem, Eric; DELORD, Jean-Pierre; Tabernero, Josep; Elez, Elena (Oxford University Press, 2023-12) -
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
Grothey, Axel; Van Cutsem, Eric; Wasan, Harpreet; Tabernero Caturla, Josep; Yoshino, Takayuki; Yaeger, Rona; Kopetz, Scott (Elsevier, 2022-06)